- Home
- PRFX vs TOVX Comparison
PRFX vs TOVX Comparison
Compare PRFX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- TOVX
- Stock Information
- Founded
- PRFX 2007
- TOVX 2001
- Country
- PRFX Israel
- TOVX United States
- Employees
- PRFX N/A
- TOVX N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- TOVX Health Care
- Exchange
- PRFX Nasdaq
- TOVX Nasdaq
- Market Cap
- PRFX 3.6M
- TOVX 3.8M
- IPO Year
- PRFX 2020
- TOVX 2006
- Fundamental
- Price
- PRFX $1.39
- TOVX $0.43
- Analyst Decision
- PRFX Hold
- TOVX Hold
- Analyst Count
- PRFX 1
- TOVX 1
- Target Price
- PRFX N/A
- TOVX N/A
- AVG Volume (30 Days)
- PRFX 185.8K
- TOVX 1.6M
- Earning Date
- PRFX 08-14-2025
- TOVX 08-12-2025
- Dividend Yield
- PRFX N/A
- TOVX N/A
- EPS Growth
- PRFX N/A
- TOVX N/A
- EPS
- PRFX N/A
- TOVX N/A
- Revenue
- PRFX N/A
- TOVX N/A
- Revenue This Year
- PRFX N/A
- TOVX N/A
- Revenue Next Year
- PRFX N/A
- TOVX N/A
- P/E Ratio
- PRFX N/A
- TOVX N/A
- Revenue Growth
- PRFX N/A
- TOVX N/A
- 52 Week Low
- PRFX $1.25
- TOVX $0.40
- 52 Week High
- PRFX $16.63
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- PRFX 33.95
- TOVX 33.63
- Support Level
- PRFX $1.25
- TOVX $0.43
- Resistance Level
- PRFX $1.76
- TOVX $0.46
- Average True Range (ATR)
- PRFX 0.10
- TOVX 0.04
- MACD
- PRFX -0.05
- TOVX 0.02
- Stochastic Oscillator
- PRFX 23.53
- TOVX 15.54
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.